CRISPR Therapeutics AG (CRSP)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in CRISPR Therapeutics AG, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

CRISPR Therapeutics AG (CRSP) has returned -9.29% so far this year and 39.79% over the past 12 months.

Based on dividend-adjusted daily data since Oct 19, 2016, CRSP's average daily return is +0.13%, while the average monthly return is +2.84%. At this rate, your investment would double in approximately 2.1 years.

Historically, 52% of months were positive and 48% were negative. The best month was Nov 2023 with a return of +71.4%, while the worst month was Oct 2018 at -26.1%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 6 months.

On a daily basis, CRSP closed higher 49% of trading days. The best single day was Feb 25, 2019 with a return of +25.2%, while the worst single day was Dec 21, 2018 at -17.1%.

CRISPR Therapeutics AG has an annualized alpha of 16.16%, beta of 1.36, and R² of 0.15 versus S&P 500 Index. Calculated based on daily prices since October 20, 2016.

• This stock captured 182.39% of S&P 500 Index gains and 159.73% of its losses — amplifying both gains and losses, but participating more in upside than downside.
• R² of 0.15 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

CRSP ranks 59 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for CRISPR Therapeutics AG (CRSP) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the CRISPR Therapeutics AG. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the CRISPR Therapeutics AG was 85.11%, occurring on Apr 8, 2025. The portfolio has not yet recovered.

The current CRISPR Therapeutics AG drawdown is 77.35%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of CRISPR Therapeutics AG over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how CRISPR Therapeutics AG is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.